资金面上，该股今日主力资金净流入173.80万元，近5日资金净流出3407.67万元。（数据宝） （文章来源：证券时报网） 特一药业（002728）1月22日发布2025年业绩预增公告，预计实现净利润为7000.00万元~9000.00万元， 净利润同比增长241.55%~339.13%。 证券时报·数据宝统计显示，特一药业今日收于11.72元，上涨1.74%，日换手率为5.72%，成交额为2.51 亿元，近5日上涨2.36%。通过对2025年业绩预增50%以上的个股走势进行统计发现，预告发布后当日股 价上涨的占比63.85%，股价发布当日股价涨停的有9家。预告发布后5日股价上涨的占比76.15%。 ...

经济观察网2026年1月22日，特一药业（002728）发布2025年度业绩预告，预计2025年净利润7000万元 至9000万元，同比增长241.55%至339.13%；扣除非经常性损益后的净利润6750万元至8750万元，同比 增长263.83%至371.64%。 ...

特一药业（002728）(002728.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润7000 万元—9000万元，同比增长241.55%—339.13%;扣除非经常性损益后的净利润6750万元—8750万元，同 比增长263.83%—371.64%。 ...

智通财经APP讯，特一药业(002728.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润 7000万元—9000万元，同比增长241.55%—339.13%;扣除非经常性损益后的净利润6750万元—8750万 元，同比增长263.83%—371.64%。 ...

Core Viewpoint - The company expects a net profit attributable to shareholders of 70 million to 90 million yuan for the fiscal year 2025, representing a year-on-year growth of 241.55% to 339.13% [1] Group 1: Performance Drivers - The current performance change is attributed to the deepening of marketing transformation, advancement of brand strategy, and product recovery [1] - Core product sales have rebounded, and marketing channel optimization has contributed to a good recovery in both operating revenue and overall gross profit margin [1] Group 2: Financial Impact - Despite short-term impacts on profits due to investments in brand building, the overall operating profit has shown positive improvement [1] - The results reflect that marketing reforms and brand development have achieved significant effectiveness [1]

每经AI快讯，特一药业1月22日晚间发布业绩预告，预计2025年归属于上市公司股东的净利润7000万元 ~9000万元，同比增长241.55%~339.13%；基本每股收益0.14元~0.18元。业绩变动主要原因是，公司当 前业绩变化是营销转型深化、品牌战略推进与产品复苏共同作用的结果。在核心产品销量回升、营销渠 道优化等因素共同推动下，公司营业收入及综合毛利率均呈现较好恢复。尽管品牌建设投入短期内对利 润带来一定影响，但公司整体营业利润仍实现积极改善，反映出营销变革与品牌建设已取得较好成效。 每经头条（nbdtoutiao）——特朗普强要格陵兰岛，丹麦一养老基金率先清仓美债，美国资产全线下 跌！欧洲手握"金融核按钮"，双方会"鱼死网破"吗？专家解读→ （记者 王晓波） ...

Core Viewpoint - The company expects a net profit of 70 million to 90 million yuan for the year 2025, representing a year-on-year growth of 241.55% to 339.13% [1] Group 1: Performance Drivers - The performance change is attributed to the deepening of marketing transformation, advancement of brand strategy, and product recovery [1] - Core product sales have rebounded, and marketing channel optimization has contributed to a good recovery in both operating revenue and overall gross profit margin [1] Group 2: Financial Impact - Despite short-term impacts on profits due to investments in brand building, the overall operating profit has shown positive improvement [1] - The results reflect that marketing reform and brand development have achieved significant effectiveness [1]

Core Viewpoint - The company, Te Yi Pharmaceutical, anticipates a significant increase in net profit for the year 2025, driven by marketing transformation, brand strategy advancement, and product recovery [1] Financial Performance - The expected net profit attributable to shareholders for 2025 is projected to be between 70 million and 90 million yuan, representing a year-on-year increase of 241.55% to 339.13% [1] - The anticipated net profit after deducting non-recurring gains and losses is estimated to be between 67.5 million and 87.5 million yuan, reflecting a year-on-year growth of 263.83% to 371.64% [1] Business Strategy - The company's performance improvement is attributed to the recovery in core product sales and optimization of marketing channels [1] - Despite short-term impacts on profits due to investments in brand building, the overall operating profit has shown positive improvement, indicating successful outcomes from marketing reforms and brand development [1]

证券代码：002728 证券简称：特一药业 公告编号：2026-002 特一药业集团股份有限公司 2025 年度业绩预告 | 项目 | 本报告期 | | | 上年同期 | | | --- | --- | --- | --- | --- | --- | | 归属于上市公司股东的净利润 | 盈利：7,000 | 万元—9,000 | 万元 | 盈利：2,049.50 | 万元 | | | 比上年同期增长：241.55%—339.13% | | | | | | 扣除非经常性损益后的净利润 | 盈利：6,750 | 万元—8,750 | 万元 | 盈利：1,855.24 | 万元 | | | 比上年同期增长：263.83%—371.64% | | | | | | 基本每股收益 | 盈利：0.14 | 元/股—0.18 | 元/股 | 盈利：0.04 | 元/股 | 二、与会计师事务所沟通情况 本次业绩预告相关数据是公司财务部门初步测算的结果，未经会计师事务所预审计。 公司已就业绩预告有关事项与会计师事务所进行了预沟通，公司与会计师事务所在业绩 预告方面不存在分歧。 三、业绩变动原因说明 公司当前业绩变化是营销转型深化 ...

Core Viewpoint - The company is focusing on expanding its market presence and enhancing the efficacy of its core product, the cough remedy "Zhi Ke Bao Pian," while preparing for potential inclusion in medical insurance programs [2][4]. Product Development and Research - The core product "Zhi Ke Bao Pian" has a history of over a century and is effective for various types of chronic cough, with a clinical effectiveness rate of 93% and a low incidence of side effects [2][4]. - Recent studies have been conducted on the product's efficacy against coughs caused by influenza and lung inflammation, with findings published in reputable journals [2]. - The company aims to strengthen its theoretical support for product promotion and consumer education through ongoing research [2]. Market Strategy - The company is implementing a mixed marketing model combining self-operated teams and promotional service providers to expand market coverage [2]. - Efforts are being made to penetrate key national chain pharmacies, deepen partnerships with O2O and B2C e-commerce platforms, and develop third-party channels such as clinics [2]. Financial Performance - For the first three quarters of 2025, the company reported total revenue of 692 million yuan, a year-on-year increase of 51.86%, and a net profit of 65.22 million yuan, up 985.18% [3]. - Sales of "Zhi Ke Bao Pian" have shown steady recovery, reaching 64% of the sales volume compared to the same period in 2023 [3]. Competitive Advantages - The company possesses significant competitive barriers, including advanced extraction technology, a robust patent system, and a strong brand reputation [4][5]. - The product's clinical validation shows high effectiveness rates for specific cough types, further solidifying its market position [4].